Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection
Standard
Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection. / Duwe, G; Knitter, S; Pesthy, S; Beierle, A S; Bahra, M; Schmelzle, M; Schmuck, R B; Lohneis, P; Raschzok, N; Öllinger, R; Sinn, M; Struecker, B; Sauer, I M; Pratschke, J; Andreou, A.
In: EJSO-EUR J SURG ONC, Vol. 43, No. 9, 09.2017, p. 1668-1681.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection
AU - Duwe, G
AU - Knitter, S
AU - Pesthy, S
AU - Beierle, A S
AU - Bahra, M
AU - Schmelzle, M
AU - Schmuck, R B
AU - Lohneis, P
AU - Raschzok, N
AU - Öllinger, R
AU - Sinn, M
AU - Struecker, B
AU - Sauer, I M
AU - Pratschke, J
AU - Andreou, A
N1 - Copyright © 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
PY - 2017/9
Y1 - 2017/9
N2 - Patients with colorectal liver metastases (CLM) have remarkably benefited from the advances in medical multimodal treatment and surgical techniques over the last two decades leading to significant improvements in long-term survival. More patients are currently undergoing liver resection following neoadjuvant chemotherapy, which has been increasingly established within the framework of curative-indented treatment strategies. However, the use of several cytotoxic agents has been linked to specific liver injuries that not only impair the ability of liver tissue to regenerate but also decrease long-term survival. One of the most common agents included in modern chemotherapy regimens is oxaliplatin, which is considered to induce a parenchymal damage of the liver primarily involving the sinusoids defined as sinusoidal obstruction syndrome (SOS). Administration of bevacizumab, an inhibitor of vascular endothelial growth factor (VEGF), has been reported to improve response of CLM to chemotherapy in clinical studies, concomitantly protecting the liver from the development of SOS. In this review, we aim to summarize current data on multimodal treatment concepts for CLM, give an in-depth overview of liver damage caused by cytostatic agents focusing on oxaliplatin-induced SOS, and evaluate the role of bevacizumab to improve clinical outcomes of patients with CLM and to protect the liver from the development of SOS.
AB - Patients with colorectal liver metastases (CLM) have remarkably benefited from the advances in medical multimodal treatment and surgical techniques over the last two decades leading to significant improvements in long-term survival. More patients are currently undergoing liver resection following neoadjuvant chemotherapy, which has been increasingly established within the framework of curative-indented treatment strategies. However, the use of several cytotoxic agents has been linked to specific liver injuries that not only impair the ability of liver tissue to regenerate but also decrease long-term survival. One of the most common agents included in modern chemotherapy regimens is oxaliplatin, which is considered to induce a parenchymal damage of the liver primarily involving the sinusoids defined as sinusoidal obstruction syndrome (SOS). Administration of bevacizumab, an inhibitor of vascular endothelial growth factor (VEGF), has been reported to improve response of CLM to chemotherapy in clinical studies, concomitantly protecting the liver from the development of SOS. In this review, we aim to summarize current data on multimodal treatment concepts for CLM, give an in-depth overview of liver damage caused by cytostatic agents focusing on oxaliplatin-induced SOS, and evaluate the role of bevacizumab to improve clinical outcomes of patients with CLM and to protect the liver from the development of SOS.
KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects
KW - Bevacizumab/administration & dosage
KW - Camptothecin/administration & dosage
KW - Cetuximab/administration & dosage
KW - Chemical and Drug Induced Liver Injury/etiology
KW - Colorectal Neoplasms/pathology
KW - Fluorouracil/administration & dosage
KW - Hepatectomy
KW - Hepatic Veno-Occlusive Disease/chemically induced
KW - Humans
KW - Irinotecan
KW - Liver Neoplasms/drug therapy
KW - Neoadjuvant Therapy
KW - Organoplatinum Compounds/administration & dosage
KW - Oxaliplatin
KW - Survival Rate
U2 - 10.1016/j.ejso.2017.05.008
DO - 10.1016/j.ejso.2017.05.008
M3 - SCORING: Review article
C2 - 28599872
VL - 43
SP - 1668
EP - 1681
JO - EJSO-EUR J SURG ONC
JF - EJSO-EUR J SURG ONC
SN - 0748-7983
IS - 9
ER -
